Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial

Abstract Endometrial cancers are characterized by frequent alterations in the PI3K-AKT-mTor, IGF1 and DNA repair signaling pathways. Concomitant inhibition of these pathways was warranted. ENDOLA phase I/II trial (NCT02755844) was designed to assess the safety/efficacy of the triplet combination of...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Max Piffoux, Alexandra Leary, Philippe Follana, Cyril Abdeddaim, Florence Joly, Sylvie Bin, Maxime Bonjour, Anais Boulai, Celine Callens, Laurent Villeneuve, Marine Alexandre, Verane Schwiertz, Gilles Freyer, Manuel Rodrigues, Benoit You
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Nature Portfolio 2025-02-01
Edice:	Nature Communications
On-line přístup:	https://doi.org/10.1038/s41467-025-56914-7
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!